Brevan Howard Capital Management »

Intellia Therapeutics shares owned by Brevan Howard Capital Management

Quarter-by-quarter ownership of Intellia Therapeutics (NTLA) shares owned by Brevan Howard Capital Management from 13F filings

Historical chart of Brevan Howard Capital Management investment in Intellia Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Intellia Therapeutics held by Brevan Howard Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Intellia Therapeutics by Brevan Howard Capital Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $1.1M 64k 17.27
2025-06-30 $207k 22k 9.38
2024-12-31 $1.3M 108k 11.66
2024-09-30 $307k 15k 20.55
2021-03-31 $3.0k 37k 0.08
2020-12-31 $3.2M 58k 54.40

More positions owned by Brevan Howard Capital Management

Alphabet Cap Stk Cl C Call Option (GOOG)
Ishares Bitcoin Trust Etf Shs Ben Int Call Option (IBIT)
Pdd Holdings Sponsored Ads Call Option (PDD)
Microsoft Corporation Call Option (MSFT)
Meta Platforms Cl A Call Option (META)
Ishares Tr Msci Emg Mkt Etf Call Option (EEM)
Ishares Tr Iboxx Hi Yd Etf Put Option (HYG)
Ishares Tr Iboxx Inv Cp Etf Call Option (LQD)
Dbx Etf Tr Xtrack Hrvst Csi Call Option (ASHR)
NVIDIA Corporation Call Option (NVDA)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Coinbase Global Com Cl A Call Option (COIN)
Baidu Spon Adr Rep A Call Option (BIDU)
Agnico Call Option (AEM)
Alphabet Cap Stk Cl A Put Option (GOOGL)

View all positions for Brevan Howard Capital Management

Top funds holding Intellia Therapeutics

ARK Investment Management
Vanguard Group
BlackRock
Contrarius Group Holdings
State Street Corporation
Goldman Sachs Group
Morgan Stanley
Regeneron Pharmaceuticals
Baker Bros. Advisors
Geode Capital Management
Two Sigma Investments
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
D. E. Shaw & Co
Two Sigma Advisers

View all funds holding Intellia Therapeutics